Журнал кардиореспираторных исследований 2024. №1

Тема статьи

KORONAVIRUS INFEKTSIYASINING ARTERIAL GIPERTENZIYA BILAN KASALLANGAN BEMORLARDA ANTIGIPERTENZIV TERAPIYA SAMARADORLIGIGA TA'SIRI (41-48)

Авторы

Atoeva M.I., Abdullaeva G. Zh., Masharipov Sh.M., Khamidullaeva G.A., Abidova D.E.

Учреждение

Respublika ixtisoslashtirilgan kardiologiya ilmiy-amaliy tibbiyot markazi

Аннотация

Tadqiqot maqsadi: gipertoniya bilan og'rigan bemorlarda 6 oylik kombinirlangan antigipertenziv terapiya samaradorligiga koronavirus infektsiyasining ta'sirini o'rganish.Materiallar va tadqiqot usullari: tadqiqotga I-III darajali gipertenziya (ESC/ESH 2018) bo’lgan , har ikki jinsdagi 30-75 yoshdagi, og'ir yondosh kasalliklari va yurak-qon tomir asoratlari bo'lmagan bemorlar ishtirok etdi (o'tkir miokard infarkti, surunkali yurak etishmovchiligi, serebrovaskulyar kasalliklar, yurak aritmiyalari, qandli diabet).Barcha bemorlarda davolanishdan oldingi bosqichda va 6 oylik antigipertenziv terapiyadan keyin ofis qon bosimi Korotkov usuli yordamida o'lchandi; qon bosimining sutkalik profilini (SPAB) o'rganish uchun 24 soatlik qon bosimi monitoringi o'tkazildi ("Registrator BR-102 plus" (SCHILLER, Shveytsariya)). Natijalar: COVID19 bilan kasallanish dastlabki ofis qon bosimi va SPAB qiymatlariga ta'sir qilmadi. Biroq, o’tkazilgan koronavirus infektsiyasi SPAB ko'rsatkichlari dinamikasi nuqtai nazaridan antigipertenziv samaradorlikka salbiy ta’sir ko’rsatgan. Shuni ta'kidlash kerakki, 6 oylik terapiya davomida qon bosimining variabelligi va tungi qon bosimi pasayish darajasi faqat COVID19 (-) gipertenziyasi bo'lgan bemorlar guruhida yaxshilandi. Xulosa: Tadqiqotimiz natijalariga ko’ra arterial gipertenziya koronavirus infektsiyasi bilan birgalikda kechganda antigipertenziv terapiya samaradorligiga salbiy ko'rsatdi. Shuni ta'kidlash kerakki, 24 soatlik qon bosimi profilining sezilarli yaxshilanishi faqat COVID19 (-) bemorlarda kuzatilgan. asi.

Ключевые слова

Kalit so'zlar: arterial gipertenziya, koronavirus infeksiyasi (COVID19), qon bosimining sutkalik profili, arterial qon bosimi variabelligi, qon bosimining tungi pasayish daraj

Литературы

1. Habas K, Nganwuchu C, Shahzad F, Gopalan R, Haque M, Rahman S, Majumder AA, Nasim T. Resolution of coronavirus disease 2019 (COVID-19). Expert Rev Anti Infect Ther. 2020;18(12):1201-1211. 2. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069. 3. Guan WJ, Ni ZY, Hu Y. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720. 4. Böger B, Fachi M, Vilhena R, Cobre A, Tonin F, Pontarolo R. Systematic review with meta-analysis of the accuracy of diagnostic tests for COVID-19. Am J Infect Control. 2021;49(1):21-29. 5. Bozkurt B, Kovacs R, Harrington B. Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID19. J Card Fail. 2020;26(5):370. 6. И.А. ЗОЛОТОВСКАЯ, Г.Р. ГИМАТДИНОВА, И.Л. ДАВЫДКИН Артериальная гипертензия у пациентов, перенесших COVID- 19: особенности и возможности коррекции артериального давления. Профилактическая медицина. 2022, Т. 25, №1, с. 63-70]. 7. Lian J, Jin X, Hao S, Cai H, Zhang S, Zheng L, Jia H, Hu J, Gao J, Zhang Y, Zhang X, Yu G, Wang X, Gu J, Ye C, Jin C, Lu Y, Yu X, Yu X, Ren Y, Qiu Y, Li L, Sheng J, Yang Y. Analysis of epidemiological and clinical features in older patients with coronavirus disease 2019 (COVID-19) out of Wuhan. Clin Infect Dis. 2020;71(15):740-747. 8. Majumder J, Minko T. Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. AAPS J. 2021;23(1):14. 9. Jiang F, Deng L, Zhang L, Cai Y, Cheung CW,